In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives. Despite current recommendations, treating ISR continues to be a challenge, and clinical…
TCT 2023 | COMPARE 60/80 HBR TRIAL
This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet therapy (DAPT). A total 747 patients were recruited, 368 received PCI with the ultrathin Superflex stent with 60 µm struts (SUF), and 364 received the Terumo Tansei with 89 µm struts (SF). Primary end point was NACE at…
TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons
This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P). Primary end point was late lumen loss (LLL) at 12 months. There were no significant differences between the groups. Mean patient age was 63, 75% were…
TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome
This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to: dual antiplatelet therapy (DAPT) with ASA and ticagrelor during one month (1,426 patients), followed by ticagrelor monotherapy for 12 months, while the other group received DAPT with ASA and ticagrelor during 12 months (1,424 patients). This study was…
TCT 2023 | SWEDEHEART, Evolution at 5 Years
This register included 42,887 patients receiving FFR or iFR to assess moderate lesions, and 80% of them underwent FFR. Population characteristics were similar, except that the iFR group had more women, with more diabetes, MI, stroke and chronic obstructive pulmonary disease (COPD). Primary end point was a composite of all cause death, MI and unplanned…